ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.15del (p.Glu7fs)

dbSNP: rs1064795072
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000661853 SCV000784178 pathogenic Breast-ovarian cancer, familial, susceptibility to, 2 2017-12-15 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
GeneDx RCV000478121 SCV000570516 pathogenic not provided 2016-05-31 criteria provided, single submitter clinical testing This deletion of one nucleotide in BRCA2 is denoted c.15delC at the cDNA level and p.Glu7ArgfsX18 (E7RfsX18) at the protein level. The normal sequence, with the base that is deleted in braces, is GATC[C]AAAG. The deletion causes a frameshift which changes a Glutamic Acid to an Arginine at codon 7, and creates a premature stop codon at position 18 of the new reading frame. Using alternate nomenclature, this variant would be defined as BRCA2 243delC. Although this variant has not, to our knowledge, been reported in the literature, it is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. We consider this variant to be pathogenic.
Ambry Genetics RCV001012309 SCV001172742 pathogenic Hereditary cancer-predisposing syndrome 2018-06-26 criteria provided, single submitter clinical testing The c.15delC pathogenic mutation, located in coding exon 1 of the BRCA2 gene, results from a deletion of one nucleotide at nucleotide position 15, causing a translational frameshift with a predicted alternate stop codon (p.E7Rfs*18). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Fulgent Genetics, Fulgent Genetics RCV002496866 SCV002814042 likely pathogenic Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 2; Fanconi anemia complementation group D1; Medulloblastoma; Wilms tumor 1; Malignant tumor of prostate; Pancreatic cancer, susceptibility to, 2; Glioma susceptibility 3 2022-01-03 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.